论文部分内容阅读
目的 探讨干扰素治疗与乙型肝炎病毒 (HBV )前C区变异 (1896位点G→A点变异 )及干扰素抗体的关系。方法 分别以PCR及ELISA方法检测 86例慢性HBV感染患者血清中HBV前C区变异株及干扰素抗体。结果 ALT >10 0IU/L组变异株检出率 (40 .4% )显著高于ALT≤ 10 0IU /L组 (8.8% ) ,两组比较差异有显著性 (P <0 .0 0 5 ) ;CHB重度组检出率明显高于慢性携带者及CHB轻度组 (P <0 .0 0 5 ) ;3 8例CHB接受干扰素治疗 ,变异株组和野生株组对干扰素近期应答率相似 ,但变异株组复发率 (70 .0 % )显著高于野生株组 (2 3 .1% ) ;干扰素抗体阳性组的近期应答率 (3 8.5 % )显著低于阴性组 (72 .0 % )。结论 变异株感染与肝病严重程度有关 ,HBV前C区变异和干扰素抗体可影响干扰素的抗病毒疗效。
Objective To investigate the relationship between interferon treatment and hepatitis B virus (HBV) precore mutation (G → A mutation at 1896) and interferon antibodies. Methods Serum samples of pre-HBV mutants and interferon antibodies of 86 patients with chronic HBV infection were detected by PCR and ELISA respectively. Results The detection rate of ALT> 100 IU / L was significantly higher than that of ALT≤10 0 IU / L (40% vs 8.8%), the difference was significant (P <0.05) ; CHB severe group detection rate was significantly higher than the chronic carriers and mild CHB group (P <0.05); 38 cases of CHB received interferon treatment, mutant strains and wild strains of interferon near-term response rate (70.0%) in mutant group was significantly higher than that in wild strain group (21.3%). The recent response rate (38.5%) in interferon antibody positive group was significantly lower than that in negative group (72.5%). 0%). Conclusion Mutant infection is related to the severity of liver disease. Variation of pre-HBV C region and interferon antibody may affect the antiviral efficacy of interferon.